Bloomberg News

Elan Says Tysabri Patients Had Reduced Annualized Relapse Rates

October 19, 2011

Oct. 19 (Bloomberg) -- Elan Corporation Plc said “key data” indicated patients on Tysabri experienced reduced annualized relapse rates, particularly in those treated early in the course of their disease.

To contact the editor responsible for this story: Dara Doyle at ddoyle1@bloomberg.net


The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus